These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 8489326)
1. Efficacy of phenelzine and haloperidol in borderline personality disorder. Soloff PH; Cornelius J; George A; Nathan S; Perel JM; Ulrich RF Arch Gen Psychiatry; 1993 May; 50(5):377-85. PubMed ID: 8489326 [TBL] [Abstract][Full Text] [Related]
2. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Cornelius JR; Soloff PH; Perel JM; Ulrich RF Am J Psychiatry; 1993 Dec; 150(12):1843-8. PubMed ID: 8238640 [TBL] [Abstract][Full Text] [Related]
3. Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Cornelius JR; Soloff PH; George A; Ulrich RF; Perel JM Psychopharmacol Bull; 1993; 29(2):333-7. PubMed ID: 8290683 [TBL] [Abstract][Full Text] [Related]
4. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Frankenburg FR; Zanarini MC J Clin Psychiatry; 2002 May; 63(5):442-6. PubMed ID: 12019669 [TBL] [Abstract][Full Text] [Related]
5. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Soloff PH; George A; Nathan RS; Schulz PM; Ulrich RF; Perel JM Arch Gen Psychiatry; 1986 Jul; 43(7):691-7. PubMed ID: 3521532 [TBL] [Abstract][Full Text] [Related]
6. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. Soloff PH; George A; Nathan S; Schulz PM; Cornelius JR; Herring J; Perel JM J Clin Psychopharmacol; 1989 Aug; 9(4):238-46. PubMed ID: 2768542 [TBL] [Abstract][Full Text] [Related]
7. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298 [TBL] [Abstract][Full Text] [Related]
8. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Nickel MK; Muehlbacher M; Nickel C; Kettler C; Pedrosa Gil F; Bachler E; Buschmann W; Rother N; Fartacek R; Egger C; Anvar J; Rother WK; Loew TH; Kaplan P Am J Psychiatry; 2006 May; 163(5):833-8. PubMed ID: 16648324 [TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. Shafti SS; Shahveisi B J Clin Psychopharmacol; 2010 Feb; 30(1):44-7. PubMed ID: 20075647 [TBL] [Abstract][Full Text] [Related]
10. Phenelzine v imipramine in atypical depression. A preliminary report. Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin J; Tricamo E; Markowitz JS; Klein DF Arch Gen Psychiatry; 1984 Jul; 41(7):669-77. PubMed ID: 6375621 [TBL] [Abstract][Full Text] [Related]
11. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. Villeneuve E; Lemelin S J Clin Psychiatry; 2005 Oct; 66(10):1298-303. PubMed ID: 16259544 [TBL] [Abstract][Full Text] [Related]
12. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Hollander E; Allen A; Lopez RP; Bienstock CA; Grossman R; Siever LJ; Merkatz L; Stein DJ J Clin Psychiatry; 2001 Mar; 62(3):199-203. PubMed ID: 11305707 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde F; Senturk V; Naudts K; Vogels C; Bernagie K; Thas O; van Heeringen C; Audenaert K J Clin Psychopharmacol; 2008 Apr; 28(2):147-55. PubMed ID: 18344724 [TBL] [Abstract][Full Text] [Related]
14. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Parsons B; Quitkin FM; McGrath PJ; Stewart JW; Tricamo E; Ocepek-Welikson K; Harrison W; Rabkin JG; Wager SG; Nunes E Psychopharmacol Bull; 1989; 25(4):524-34. PubMed ID: 2698483 [TBL] [Abstract][Full Text] [Related]
15. Phenelzine for chronic depression: a study of continuation treatment. Harrison W; Rabkin J; Stewart JW; McGrath PJ; Tricamo E; Quitkin F J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558 [TBL] [Abstract][Full Text] [Related]
16. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486 [TBL] [Abstract][Full Text] [Related]
17. Antidepressant specificity in atypical depression. Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282 [TBL] [Abstract][Full Text] [Related]
18. Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences. Henry C; Mitropoulou V; New AS; Koenigsberg HW; Silverman J; Siever LJ J Psychiatr Res; 2001; 35(6):307-12. PubMed ID: 11684137 [TBL] [Abstract][Full Text] [Related]
19. Risk factors for suicidal behavior in borderline personality disorder. Soloff PH; Lis JA; Kelly T; Cornelius J; Ulrich R Am J Psychiatry; 1994 Sep; 151(9):1316-23. PubMed ID: 8067487 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. Bellino S; Paradiso E; Bogetto F J Clin Psychiatry; 2006 Jul; 67(7):1042-6. PubMed ID: 16889446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]